argenex (NASDAQ:ARGX – Get Free Report) and Evaxion A/S (NASDAQ:EVAX – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.
Analyst Ratings
This is a summary of recent ratings and target prices for argenex and Evaxion A/S, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| argenex | 0 | 5 | 17 | 2 | 2.88 |
| Evaxion A/S | 1 | 0 | 5 | 0 | 2.67 |
argenex currently has a consensus price target of $1,158.61, indicating a potential upside of 17.49%. Evaxion A/S has a consensus price target of $11.00, indicating a potential upside of 253.02%. Given Evaxion A/S’s higher possible upside, analysts plainly believe Evaxion A/S is more favorable than argenex.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| argenex | $4.25 billion | 14.52 | $1.29 billion | $26.04 | 37.87 |
| Evaxion A/S | $7.49 million | 3.47 | -$7.71 million | ($1.21) | -2.58 |
argenex has higher revenue and earnings than Evaxion A/S. Evaxion A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares argenex and Evaxion A/S’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| argenex | 32.19% | 43.59% | 36.66% |
| Evaxion A/S | N/A | -61.43% | -34.23% |
Insider & Institutional Ownership
60.3% of argenex shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 2.4% of argenex shares are owned by company insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
argenex has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500.
Summary
argenex beats Evaxion A/S on 13 of the 15 factors compared between the two stocks.
About argenex
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
About Evaxion A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
